Congratulations to V Formation client, XenoGesis, who is celebrating its 5th successful year in business.
XenoGesis marked its 5th anniversary with a team celebration held at BioCity Nottingham. The company’s birthday marks a significant milestone for XenoGesis, which has seen year-on-year growth since its formation in November 2011.
XenoGesis was born out of the closure of AstraZeneca’s Charnwood site in Loughborough. Spotting an opportunity in the market, and disillusioned by the state of the Pharma industry, Dr Richard Weaver set up the company at BioCity Nottingham with support from private investors.
The team has grown from three to twenty three in five years, taking on more lab space at BioCity and now works with over 100 clients across the globe.
The company is now the UK’s largest independent laboratory-based contract research organisation specialising in preclinical drug metabolism and pharmacokinetics (DMPK), quantitative bioanalysis and expert interpretation.
Reflecting on the last five years, Richard said, “The secret to the success of XenoGesis has been our clear vision and 5 year plan, which we have stuck to and exceeded. But moreover, we could not have got to where we are today without the team, who collectively have an enviable track record of delivery in drug discovery. “
He continued, “We know that there is a real need for scientific experimental capability in DMPK, and our clients value the true partnership and consultative approach that we take to help them achieve their drug discovery goals.”
V Formation Director Sue Carr has worked with XenoGesis since 2012, providing strategic direction and tactical marketing support that has helped to grow the business.